Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to investigate the remission rate of patients treated with Telitacicept combined with Rituximab in remission-induction and Telitacicept alone in remission-maintain treatment.

NCT Number	NCT05962840
Lead Sponsor	Chinese SLE Treatment And Research Group Collaborators: Peking Union Medical College Hospital
Conditions	ANCA Associated Vasculitis
Enrollment	40 participants
Start Date	2023-06-29
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2023-07-27